CAS: 11024-24-1; Digitonin

该化合物是一个来自Digitis Purpurea(俗称狐群)植物的晶体,主要用于生物化学和药理学,因为它能够选择性地溶解膜蛋白,使其在细胞膜及其成分研究中具有价值.Digitonin有一个复杂的结构,其特点是一种与糖味相连的类固醇脊椎,它有助于其非曲直的特性.这种特性允许它与脂质双层相互作用,促进提取膜蛋白质,同时保持其功能完整性.除了生物化学应用外,还对某些细胞种类的数字化物展示了细胞毒性效应,这对其在研究和潜在治疗环境中的使用有影响.重要的是要小心地处理数码素,因为它在高浓度下可能有毒性.总体来说,数字素是研究膜生物学和与膜有关的蛋白质隔离的关键工具.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    专利信息


    专利号:US-2012190064-A1
    优先权日:2004-10-01
    标题 :Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
    发明人:KUDLICKI WIESLAW ANTONI; KEPPETIPOLA SHIRANTHI; FLETCHER JULIA; GETBEHEAD ASHLEY ELAINE; KATZEN FEDERICO; VOZZA-BROWN LAURA
    权利人:KUDLICKI WIESLAW ANTONI; KEPPETIPOLA SHIRANTHI; FLETCHER JULIA; GETBEHEAD ASHLEY ELAINE; KATZEN FEDERICO; VOZZA-BROWN LAURA; LIFE TECHNOLOGIES CORP
    摘要:Compositions, methods and kits for in vitro systems for synthesis of biomolecules such as polypeptides, are provided herein. Cell extracts that provide enhanced yields of soluble proteins using in vitro protein synthesis methods are provided. The invention also includes methods for producing high yields of proteins by the addition of a feeding solution that includes amino acids and an energy source to an ongoing in vitro synthesis system. The invention also includes methods of using a high-yield in vitro synthesis system to produce large quantities of proteins with incorporated labeled amino acids for analysis by methods such as by NMR. The invention further includes vectors for enhanced production of proteins from nucleic acid templates using in vitro synthesis systems.

    专利号:US-6767723-B2
    优先权日:2000-04-27
    标题 :Method for synthesis of nucleic acids
    发明人:TONOIKE HIROSHI
    权利人:SHIMADZU CORP
    摘要:An object of the present invention is to provide a method of treatment and a method of storage that are useful in conducting a nucleic acid synthesis procedure capable of directly amplifying an intended nucleic acid in a living body-derived sample without purification steps.The present invention provides a method for synthesis of nucleic acids in which a living body-derived sample itself is mixed with a reaction solution for gene amplification and allowed to react, which method comprises treating the sample with a surfactant before the reaction to destruct solid components such as cells or bacterial bodies containing nucleic acids and uniformly disperse them in the sample liquid.

    专利号:US-4739073-A
    优先权日:1983-11-04
    标题:Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
    发明人:KATHAWALA FAIZULLA G
    权利人:SANDOZ PHARMACEUTICALS CORP
    摘要:Compounds of the formula wherein one of R and Ro is and the other is primary or secondary C1-6alkyl not containing an asymmetric carbon atom, C3-6cycloalkyl or phenyl(CH2)m-, wherein R4 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5a is hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R5 and R5a must be hydrogen when R4 is hydrogen, R5a must be hydrogen when R5 is hydrogen, not more than one of R4 and R5 is trifluoromethyl, not more than one of R4 and R5 is phenoxy, and not more than one of R4 and R5 is benzyloxy, R2 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C3-6cycloalkyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R3 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R3 must be hydrogen when R2 is hydrogen, not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, and not more than one of R2 and R3 is benzyloxy, X is -(CH2)n- or -CH=CH-, wherein n is 0, 1, 2 or 3, and Z is wherein R6 is hydrogen or C1-3alkyl, and R7 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, benzyl or M, wherein M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

    专利号:US-6015808-A
    优先权日:1993-08-20
    标 题 :Synthesis of pharmaceutical compositions with lactams and β-lactams/oxo thia azabicyclo compounds
    发明人:THIRUMALACHAR MANDAYAM JEERSAN; NARASIMHAN JR MANDAYAM JEERSAN
    摘要:Pharmaceutical compositions with heretofore unknown and enhanced physical, chemical, and biological properties are prepared by combining known biologically active parent compounds with oxo thia azabicyclo compounds, such as lactam and beta -lactam compounds, capable of rapidly transporting the parent compounds in undegraded form to their target sites of action. A process for combining the parent compound with beta -lactam compounds consists of dissolving the parent compound in a polar solvent, adding a beta -lactam compound, incubating the resulting mixture, followed by drying, and subjecting the remaining solid material to solvent washing or extraction to further purify the new pharmaceutical composition. The new pharmaceutical composition possesses the biological and therapeutic activity of the parent compound and the barrier penetrating characteristics of the beta -lactam compound, which results in improved pharmacodynamics, including bioavailability, and an improved chemotherapeutic index, such that lower amounts of the parent may be used to avoid the toxic effects of the parent compound. Some of the new pharmaceutical compounds provide for the first time parent compounds in an orally administerable form.

    专利号:US-4411916-A
    优先权日:1980-11-24
    标题 :Method of producing milk factor
    发明人:MANN GEORGE V
    权利人:UNIV VANDERBILT
    摘要:The substance naturally present in milk (referred to as Milk Factor or MF) which is capable of inhibiting mammalian synthesis of cholesterol is produced by a fermentation process using a culture of Pseudomonas fluorescens loitokitok or other Milk Factor-producing strain of P. fluorescens in a culture medium containing glutaconic acid. The process may be used to increase the Milk Factor content of milk, yogurt, or similar dairy product, or the Milk Factor may be recovered from a culture medium and concentrated, crystallized and used as a food additive.

    专利号:US-4613610-A
    优先权日:1984-06-22
    标题 :Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
    发明人:WAREING JAMES R
    权利人:SANDOZ PHARMACEUTICALS CORP
    摘要:Compounds of the formula wherein R1 is C1-6alkyl not containing an asymmetric carbon atom, each of R2 and R5 is independently hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenyl, phenoxy or benzyloxy, each of R3 and R6 is independently hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, each of R4 and R7 is independently hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, with the provisos that not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, not more than one of R2 and R3 is benzyloxy, not more than one of R5 and R6 is trifluoromethyl, not more than one of R5 and R6 is phenoxy, and not more than one of R5 and R6 is benzyloxy, X is -(CH2)m-, -CH=CH-, -CH=CH-CH2- or -CH2-CH=CH-, wherein m is 0, 1, 2 or 3, and Z is wherein R10 is hydrogen or C1-3alkyl, wherein R12 is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, with the provisos that (i) the-X-Z group is in the 4- or 5-position of the pyrazole ring, and (ii) the R1 group and the -X-Z group are ortho to each other, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.
    浙江省台州台美精细化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:13615865956👤
    ⚠️参考联系方式
    销售经理: 卓小姐经理
    联系电话:13615865956
    手机号码: 13615865956
    浙江省台州市椒江区工人西路
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    浙江省台州市椒江区工人西路
    ⚠️ 未注册 · 未认证企业
    注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
    西安市大宇化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:0135-72227049👤
    ⚠️参考联系方式
    邮件:xadyhg@126.com
    销售经理: 宋武宁经理
    联系电话:0135-72227049
    手机号码: 13572227049
    传真号码: 029-68573000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    高新区唐延路25号
    ⚠️ 未注册 · 未认证企业
    注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
    上海丹尼尔化学技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:021-36162230 13701606051👤
    ⚠️参考联系方式
    地址:上海市宝山城市工业园区园辉路336号. 邮编:200444
    电话:021-36162230 13701606051
    传真:021-36160680
    邮箱:ping.shen@dannier.com
    联系人:沈平
    手机:13701606051
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    上海市宝山城市工业园区园辉路336号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    成都润泽本土化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:028-88469284👤
    ⚠️参考联系方式
    销售经理: 刘经理
    联系电话:028-88469284
    手机号码: 13096311329
    传真号码: 028-88469284
    QQ号:1397614349、616445927
    成都市龙泉驿国家经济开发区
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    成都市龙泉驿国家经济开发区
    ⚠️ 未注册 · 未认证企业
    注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Sciuto KJ, Deng SW, Venable PW, Warren M, Warren JS, Zaitsev AV. Cyclosporine-insensitive mode of cell death after prolonged myocardial ischemia: Evidence for sarcolemmal permeabilization as the pivotal step. PLoS One. 2018 Jul 5;13(7):e0200301. doi: 10.1371/journal.pone.0200301. eCollection 2018. doi: 10.1016/j.bpj.2018.04.047.
    3: Wang M, Wu B, Shah SN, Lu P, Lu Q. Saponins as Natural Adjuvant for Antisense Morpholino Oligonucleotides Delivery In Vitro and in mdx Mice. Mol Ther Nucleic Acids. 2018 Jun 1;11:192-202. doi: 10.1016/j.omtn.2018.02.004. Epub 2018 Feb 21.
    4: Chan WY, Lau PM, Yeung KW, Kong SK. The second generation tyrosine kinase inhibitor dasatinib induced eryptosis in human erythrocytes-An in vitro study. Toxicol Lett. 2018 May 24;295:10-21. doi: 10.1016/j.toxlet.2018.05.030. [Epub ahead of print] doi: 10.1080/21505594.2018.1454171.

    合成参考文献


    参考文献:10.1371/journal.pone.0008181
    摘要:Gellerich FN, Gizatullina Z, Arandarcikaite O, Jerzembek D, Vielhaber S, Seppet E, Striggow F. Extramitochondrial Ca2+ in the Nanomolar Range Regulates Glutamate-Dependent Oxidative Phosphorylation on Demand. PLoS ONE. 2009 Dec 09;4(12):e8181. doi: 10.1371/journal.pone.0008181.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知